Myoma;Uterus Clinical Trial
Official title:
The Efficacy Of Misoprostol Versus Oxytocin Infusion On Reducing Blood Loss During Abdominal Myomectomy
Uterine leiomyomas, or fibroids, are common benign tumors among women, especially those over 35 years old. They can cause various issues, including heavy menstrual bleeding, anemia, pelvic pain, and pressure symptoms. Surgery is often necessary for symptomatic fibroids, with hysterectomy recommended for women over 40 and myomectomy for those wishing to preserve their uterus. Myomectomy can be performed using different surgical approaches but can be associated with significant morbidity, particularly major blood loss, especially in abdominal myomectomy, where up to 20% of women may require blood transfusion. Various interventions have been introduced to reduce bleeding during myomectomy, such as tourniquets, bupivacaine plus epinephrine infiltration, vasopressin injection, preoperative GnRH agonist administration, and preoperative ascorbic acid injection. However, these strategies may have complications, be ineffective, expensive, or require extra steps. Oxytocin, primarily secreted from the pituitary gland, is crucial for uterine contraction during labor and delivery, and is used to prevent postpartum uterine atony and bleeding. However, caution is needed in its use, especially in women with heart disease or hypovolemia. Misoprostol, a prostaglandin E1 analogue, can reduce bleeding during myomectomy by promoting myometrial contractions and reducing uterine artery blood flow. It can be administered via multiple routes, with rectal administration showing advantages in maintaining high plasma concentrations during surgery. Studies have investigated the effectiveness of single preoperative rectal doses of misoprostol versus preoperative oxytocin in reducing bleeding during abdominal myomectomy.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04519593 -
ABSOLUTELY: A Temporary Uterine Blood Supply Occlusion for Laparoscopic Myomectomy in Patients With UTErine LeiomYoma
|
N/A | |
Active, not recruiting |
NCT06114758 -
Comparison Effectiveness of Rectal Misoprostol & Intravenous Tranexamic Acid Reducing Hemorrhage in Myomectomy
|
||
Not yet recruiting |
NCT05967936 -
Paracervical Block Versus Transcervical Block in Outpatient Procedural Hysteroscopy
|
N/A | |
Not yet recruiting |
NCT05932082 -
The Impact of Myomectomy on IVF Outcomes
|
N/A | |
Recruiting |
NCT04748978 -
OPPIuM Technique and Myolysis With Diode Laser Dwls
|
N/A | |
Recruiting |
NCT05271981 -
Fertility After Uterine Artery Embolization
|
||
Completed |
NCT05025410 -
Remimazolam and Remifentanil Without Neuromuscular Blocking Agent
|
||
Recruiting |
NCT03483142 -
the Effect of Misoprostol on Intra-operative Blood Loss During Myomectomy Operation
|
Phase 3 | |
Completed |
NCT03533907 -
Pregnancy Outcomes in Infertile Patients After Treatment With Ulipristal Acetate.
|
||
Completed |
NCT05811286 -
The Use of a Morcellator in Operative Hysteroscopy for Benign Intracavitary Lesions: a Feasibility Study
|
N/A | |
Not yet recruiting |
NCT03570879 -
Laparoscopic Myomectomy With Morcellation or Transvaginal Extraction of Surgical Specimens.
|
||
Not yet recruiting |
NCT04364581 -
Endometrial Preparation by Short Course of Letrozole Before Hysteroscopic Removal of Endocavitary Lesions
|
Phase 4 | |
Recruiting |
NCT06067971 -
Evaluation of the Feasibility of Using Augmented Reality in Laparoscopic Surgery, by a Clinical Study During Gynecological Laparoscopic Surgical Procedures. (ENDORA2)
|
N/A | |
Recruiting |
NCT04990076 -
Ultrasound Evaluation of the Myometrium Using the MUSA Terminology Comparison With Histology
|
||
Completed |
NCT05761418 -
Preoperative Vaginal Dinoprostone Versus Misoprostone in Abdominal Myomectomy
|
Phase 3 | |
Recruiting |
NCT04311073 -
Prophylactic Tranexamic Acid During Minimally Invasive Myomectomies
|
Phase 3 | |
Active, not recruiting |
NCT05930769 -
Retrospective Study on the Evaluation of the Impact of Augmented Reality Usage in Gynecological Laparoscopy on Patients Operated Between 2017 and 2021 (ImpactRA)
|
||
Recruiting |
NCT03550703 -
Open Label Immunotherapy of Myoma
|
Phase 2 | |
Completed |
NCT04482959 -
Intraoperative Carbetocin to Decrease Blood Loss During Hysteroscopic Myomectomy
|
Phase 4 | |
Not yet recruiting |
NCT04030273 -
Prevalence of Intrauterine Adhesions After Abdominal Myomectomy
|